Itdhiamornkulchai S.Preutthipan A.Vaewpanich J.Anantasit N.Mahidol University2023-06-182023-06-182022-03-01Clinical and Experimental Pediatrics Vol.65 No.3 (2022) , 136-141https://repository.li.mahidol.ac.th/handle/20.500.14594/86805Background: High-flow nasal cannula (HFNC) is a noninva-sive respiratory support that provides the optimum flow of an air-oxygen mixture. Several studies demonstrated its usefulness and good safety profile for treating pediatric respiratory distress patients. However, the cost of the commercial HFNC is high; therefore, the modified high-flow nasal cannula was developed. Purpose: This study aimed to compare the effectiveness, safety, and nurses’ satisfaction of the modified system versus the standard commercial HFNC. Methods: This prospective comparative study was performed in a tertiary care hospital. We recruited children aged 1 month to 5 years who developed acute respiratory distress and were admitted to the pediatric intensive care unit. Patients were assigned to 2 groups (modified vs. commercial). The effectiveness and safety assessments included vital signs, respiratory scores, intubation rate, adverse events, and nurses’ satisfaction. Results: A total of 74 patients were treated with HFNC. Thirty-nine patients were assigned to the modified group, while the remaining 35 patients were in the commercial group. Intubation rate and adverse events did not differ significantly between the 2 groups. However, the commercial group had higher nurses’ satisfaction scores than the modified group. Conclusion: Our findings suggest that our low-cost modified HFNC could be a useful respiratory support option for younger children with acute respiratory distress, especially in hospital settings with financial constraints.NursingArticleSCOPUS10.3345/cep.2020.014032-s2.0-8512719681727134148